PRECISION MEDICINE
AND THE FUTURE
OF GENOMICS
PMFG 2024 SUMMIT

Dr. Raghib Ali

Professor Raghib Ali is the CEO, Chief Investigator and Chief Medical Officer of Our Future Health; a Clinical Epidemiologist at the University of Cambridge; a Consultant in Acute Medicine at the Oxford University Hospitals NHS Trust; and Honorary Consultant with the Office for Health Disparities and Improvement.

He graduated from Cambridge University and has been awarded postgraduate degrees in Epidemiology and Public Health from the Universities of London, Cambridge and Oxford and is a Fellow of the Royal College of Physicians. He has been involved in population health research since 2004 nationally and globally, working firstly on UK Biobank, then leading studies of cancer incidence by ethnic group in England and India from 2005 to 2013 and established the UAE Healthy Future Study, in 2014, for which he is the principal investigator.

He was awarded an OBE in the Queen’s Birthdays Honours 2022 for services to the NHS and the Covid-19 response and elected as an Honorary Fellow of the Faculty of Public Health, ‘the highest accolade the Faculty can bestow and is awarded to those who have given exceptional service to the science, literature or practice of public health’ in April 2023.

Emanuele Bosi

He is a physician scientist and Professor of Endocrinology at Università Vita-Salute San Raffaele. He serves as Head of the General Medicine, Diabetes, and Endocrinology Department, and Director of both the Diabetes Research Institute and the Post-Graduate School of Endocrinology at Ospedale San Raffaele. Bosi graduated in Medicine from the University of Milan, where he also specialized in diabetes, metabolic diseases, and clinical immunology. His research focuses on diabetes prediction, prevention, and new treatments, including technologies for blood glucose monitoring. He leads the TrialNet Clinical Center at San Raffaele, part of an NIH-funded network conducting trials in type 1 diabetes. Bosi is a member of several scientific societies, an editorial board member for various journals, and a scientific advisor to numerous pharmaceutical and biotech companies. He has published over 150 scientific papers.

Dr. Nicolas Encina

Nic Encina is the Director of Strategy & Cofounder of the Precision Population Health program at Ariadne Labs, Harvard School of Public Health, and Brigham & Women’s Hospital, and he is also Executive Director & Cofounder of the International Consortium on Newborn Sequencing (ICoNS), which holds an annual conference and is spearheading the harmonization of learnings across global programs. Nic is a successful entre- and intra-preneur, having started a series of successful software companies, biotech companies, and many successful intrapreneurial ventures, such as an innovation lab for PerkinElmer, a Harvard research program, and flagship product lines for publicly traded companies. Nic holds graduate degrees in Stem Cell Biology, Computer Science, and an MBA from Yale, with his graduate work conducted in the BLAST lab of Washington University Medical School, as part of the Human Genome Project.

Dr. Khalid Fakhro / Chair

Dr. Khalid Fakhro is the Chief of Research and Director of the Precision Medicine Program at Sidra Medicine, the largest tertiary care women and children hospital in Qatar. Dr. Fakhro leads the Laboratory of Genomic Medicine, which focuses on bringing emerging genomic technologies from the lab close to the patient’s bedside. Over the past decade, his group has sequenced thousands of genomes from patients and volunteers across the Middle East, leading gene discovery efforts for a wide range of rare disorders, as well as landmark studies on population structure, genome structural variation, and the role of Islamic ethics in genome research. To date, his lab has been awarded competitive grants exceeding $7m to study genome structure and the genetic etiology of rare diseases and Autism, and their discoveries have featured in high-impact journals worldwide. In addition to research and hospital duties, Dr. Fakhro serves multiple leadership roles in Qatar’s growing biomedical ecosystem, including as a Board Member of the Qatar Precision Medicine Institute, and Adjunct Faculty at both Weill-Cornell Medical College and Hamad Bin Khalifa University, where he teaches and supervises Masters and Ph.D. students in genomics and precision medicine.

Dr. Haydar Frangoul

Dr. Haydar Frangoul, MD, MS. is the Director of the Pediatric Stem Cell Transplant program at the Sarah Cannon Research Institute and Tristar Centennial Children's Hospital and in Nashville Tennessee. Dr Frangoul completed his MD degree at the American University of Beirut followed by Pediatric residency at Duke University. He then went to complete a fellowship in Pediatric Hematology/Oncology and Stem Cell Transplant at the University of Washington and the Fred Hutchinson Cancer Center. He was the Carolyn Perot Rathjen Endowed Professor of Pediatric Hematology/Oncology at Vanderbilt University until 2015 when he joined Sarah Cannon Research Institute to lead the Pediatric Stem Cell Transplant Program.

Dr Frangoul had leadership positions in the Children Oncology group, and Pediatric Blood and Marrow Transplant Consortium. His primary interest is allogeneic stem cell transplant using an alternative donor sources especially for non-malignant diseases. Dr Frangoul has authored or co-authored more than 140 peer reviewed manuscripts. He has been an invited speaker at numerous national and international conferences.  He is the lead investigator for the clinical trial using CRISPR-Cas9 gene editing for patients with sickle cell disease.

Peter Goodhand

Chief Executive Officer, Global Alliance for Genomics in health (GA4GH) & President, GA4GH Inc. at Global Alliance for Genomics in Health (GA4GH)

Peter Goodhand is the CEO of the Global Alliance for Genomics and Health. Prior to helping create GA4GH in 2012 he was the President and CEO of the Canadian Cancer Society. Before moving to the charitable sector he held several executive positions in the medical technology industry.

Hakon Hakonarson

Director, Center for Applied Genomics

Dr. Hakonarson is director of the Center for Applied Genomics and professor of Pediatrics at the Perelman School of Medicine, University of Pennsylvania. He leads a $40 million commitment from Children’s Hospital of Philadelphia to genomically characterize approximately 100,000 children, an initiative that has gained nationwide attention in the Wall Street Journal, New York Times, Time Magazine, Nature, and Science.

Prof. Chantal Mathieu

Chantal Mathieu is a physician-scientist who has contributed to the field of diabetes and endocrinology through basic and clinical research. Her basic research work focuses on pathogenesis and prevention of type 1 diabetes. Prof. Mathieu’s clinical work involving new products and treatment paradigms in diabetes, such as new insulins, adjunct therapies and diagnosis of gestational diabetes have made her a speaker in international fora. Prof. Mathieu coordinates the European clinical trial network for interventions in type 1 diabetes ‘INNODIA’ and the European project ‘EDENT1FI’ on screening for type 1 diabetes. Prof. Mathieu is president of EASD and vice-president of the European Diabetes Forum.

Dr. Wan Yue

Yue Wan is the Deputy Executive Director of the Genome Institute of Singapore, A*STAR. She received her B.Sc in Cell Biology and Biochemistry from the University of California, San Diego. She obtained her Ph.D. in Cancer Biology from Stanford University, USA, under the mentorship of Howard Y. Chang.  During her Ph.D., she developed the first high-throughput method for probing RNA structures genome-wide.  Yue is a recipient of the NSS-PhD scholarship from Agency for Science, Technology, and Research (A*STAR) in Singapore.  She was a Society in Science- Branco Weiss Fellow, EMBO Young Investigator, and CIFAR-Azrieli Global Scholar. Yue is also a recipient of the Young Scientist Award and L’Oreal-UNESCO for Women in Science, Singapore National Fellowship. Recently, Yue is also a participant of the international Welcome Leap RNA Readiness and Response program. Yue is interested in studying functional RNA structures and developing new versions of RNA as vaccines and therapeutics.